* Co-Diagnostics Inc reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -20 cents. The lone analyst forecast for the quarter was for a loss of 33 cents per share.

* Revenue fell 73.9% to $641.14 thousand from a year ago; analysts expected $375.00 thousand.

* Co-Diagnostics Inc's reported EPS for the quarter was a loss of 32 cents​.

* The company reported a quarterly loss of $9.7 million.

* Co-Diagnostics Inc shares had fallen by 3.2% this quarter and lost 9.0% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 2.9% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the advanced medical equipment & technology peer group is also "hold"

Wall Street's median 12-month price target for Co-Diagnostics Inc is 1.50 This summary was machine generated from LSEG data November 8 at 04:58 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.33 -0.32 Beat

Jun. 30 2024 -0.34 -0.14 Beat

Mar. 31 2024 -0.21 -0.31 Missed

Dec. 31 2023 -0.20 -0.50 Missed